Kansas selects NPLEx to track PSE purchases
This article was originally published in The Tan Sheet
Executive Summary
Kansas becomes the fifth state to take up the Consumer Healthcare Products Association's offer to monitor methamphetamine precursor purchases at no cost to the state. Missouri, Illinois, Kentucky and Louisiana have already said they will implement the industry-funded National Precursor Log Exchange to help enforce purchase limits for pseudoephedrine-containing OTCs. CHPA announced the Kansas Board of Pharmacy's decision March 22. While Mississippi recently became the second state to make all PSE drugs available Rx only, CHPA hopes other states will elect to use the tracking system (1"The Tan Sheet" Feb. 8, 2010)
You may also be interested in...
Louisiana kicks off PSE e-tracking
Louisiana implements the National Precursor Log Exchange June 15 to monitor purchases of OTC products containing pseudoephedrine. Industry bears the cost of deploying and supporting NPLEx through the Consumer Healthcare Products Association, which advocates for electronic tracking of methamphetamine precursors over prescription-only status (1"The Tan Sheet" March 29, 2010, In Brief). Louisiana Gov. Bobby Jindal called NPLEx "a critical tool to help crack down on the sale of drugs that are used to produce meth." Kentucky and Illinois also fully implemented NPLEx. Alabama, Florida, Iowa, Kansas, Missouri, South Carolina and Washington State passed legislation to adopt the NPLEx system, but have yet to implement it, according to CHPA. Oklahoma and Arkansas use separate e-tracking systems. Oregon and Mississippi shifted PSE products to Rx-only availability
Mississippi PSE Prescription Switch Will Not Start An Avalanche - CHPA
Mississippi lawmakers' decision to make all pseudoephedrine-containing drugs prescription-only will not prompt other states combating methamphetamine to do the same, the Consumer Healthcare Products Association predicts
2022 Korean VC Financings Led By Mid-Stage Bioventures
Amid a generally harsh environment, venture capital investors in South Korea appeared to take a more selective approach in 2022, with more established and financially stable domestic bioventures the biggest beneficiaries.